BioXcel Therapeutics selects Teva as stalking horse for $57.5M sale
BioXcel Therapeutics has picked Teva as the stalking horse for a $57.5M asset sale, with up to $87.5M in milestones.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.